Irritable Bowel Syndrome (IBS): Why Standard Protocols Don't Work and How the Microbiome Changes the Rules of the Game

Біговий захід GoMove в Ужгороді за підтримки Ediens

Introduction:

The blind spot of classical gastroenterology Irritable bowel syndrome (IBS) is today one of the most common reasons for referral to gastroenterologists worldwide. This functional disorder is accompanied by chronic pain, flatulence, bloating and motility disorders (diarrhea or constipation), which significantly reduce the quality of life of patients. However, for many doctors, patients with IBS become the most difficult: they seek help for years, undergo numerous examinations that do not show organic pathologies (for example, a clean colonoscopy), and ultimately lead doctors to professional burnout due to the inability to provide lasting relief.

The main problem is that conventional medicine continues to treat IBS using outdated one-size-fits-all protocols. These protocols are mostly focused on symptom relief with antispasmodics, antidepressants, or blindly prescribing probiotics or antibiotics. However, this “finger pointing” approach does not provide a stable result, as it ignores the fundamental cause of the disorder — individual disturbances in the intestinal microbiome and its connection with the central nervous system.

Why don't the protocol approach and mass-market probiotics work?

Conventional medicine is often called protocol medicine: patients with different physiological characteristics but the same symptoms are treated according to a single regimen. However, each person's microbiome is completely unique.

Today, self-medication or prescription by doctors of so-called "multi-strain" probiotics, which contain 20-30 different types of bacteria in one capsule, has become very popular. From the point of view of modern science, this is extremely harmful. When a patient with IBS consumes such a mass-market product, a large number of foreign strains begin to compete fiercely for resources in the intestine, suppressing not only pathogens, but also the patient's own (commensal) protective flora. Without creating an individual "omics profile", prescribing any bacteria is a game of roulette: what will help one patient may cause severe exacerbation of flatulence in another.

The Gut-Brain Axis and the Enteric Nervous System

To understand IBS, it is necessary to move away from the idea of the gut as a simple “tube for digesting food.” In fact, the gut has its own autonomous system, the enteric nervous system (ENS), which contains between 100 and 500 million neurons (which is comparable to the size of a cat’s brain). The ENS communicates directly with the central nervous system via the vagus nerve.

Interestingly, 90% of the signals along the vagus nerve go from the gut to the brain, and only 10% go in the opposite direction. The bacteria that inhabit our intestines are able to produce neurotransmitters such as serotonin (which controls peristalsis and mood), GABA (gamma-aminobutyric acid), dopamine, and norepinephrine. In IBS, this two-way communication is disrupted due to dysbiosis.

There is a hypersensitivity (excessive sensitivity) of intestinal receptors, which causes pain even during normal physiological contractions. Severe stress further suppresses beneficial bacteria, creating a vicious circle: dysbiosis provokes anxiety and pain, and stress and anxiety exacerbate intestinal dysbiosis.

Specific biomarkers of IBS in the microbiome

Thanks to sequencing of microbial genes (16S rRNA) and metabolomic analysis, scientists were able to clearly identify what exactly goes wrong in the intestines of patients with IBS.

Loss of biodiversity and pH change: Patients with IBS have a significant decrease in flora diversity (Shannon index) and a shift in pH to the alkaline side, which promotes the development of putrefactive processes and the proliferation of pathogens.
Deficiency of butyrate-producing bacteria: One of the main markers of IBS is a sharp decrease in butyrate-producing bacteria, particularly Faecalibacterium prausnitzii and Roseburia . Butyrate is the main source of energy for intestinal cells, protects the mucosal barrier and suppresses inflammation. Its deficiency leads to increased permeability of the walls ("leaky gut syndrome").
Excess of pathogens and LPS-producing bacteria: Against the background of the loss of protective bifido- and lactobacilli, patients are overrun by gram-negative bacteria containing lipopolysaccharides (LPS), such as Escherichia coli (pathogenic strains), Klebsiella , Proteus , and fungi of the genus Candida . LPS are potent endotoxins that penetrate damaged epithelium into the blood, causing chronic low-grade systemic inflammation.

Innovative solution: 4P-Medicine and Pharmabiotics

The modern approach to treating IBS is based on the principles of 4P medicine (personalized, predictive, preventive, patient-centered). Instead of masking symptoms, treatment should begin with restoring the body's microbial core.

Step 1: In-depth diagnostics .

The first step is a precise genetic study of the patient's intestinal microbiome. This allows us to identify specific microbial "causative agents" of inflammation or flatulence, understand the metabolic picture, and assess the state of the immune barrier.

Step 2: Targeted correction with pharmabiotics .

Based on the results, the patient is prescribed not just random probiotics, but pharmabiotics - new generation biological preparations with proven clinical effect. The uniqueness of the approach lies in the fact that the author's strains of pharmabiotics (for example, specific lines of L. plantarum or L. rhamnosus ) are selected in such a way as to purposefully inhibit (suppress) the identified opportunistic microorganisms, and at the same time not affect the client's own beneficial lacto- and bifidobacteria. This process continues in certain courses (for example, 14 days) with the necessary pauses to consolidate the effect.

Step 3: Personalized nutrition .

Since food is the main substrate for our microbes, the next step is to develop a personalized nutrition plan. Artificial intelligence algorithms analyze the patient’s microbiome and their comorbidities to create a diet that will stimulate the growth of the bacteria that are lacking (for example, adding specific fiber to increase levels of F. prausnitzii ).

Step 4: Individual microbiota bank .

The ultimate achievement of personalized medicine is the creation of one's own bank of commensal microbiota. By preserving one's healthy flora today, the patient receives "biological insurance." In the event of future severe stress or antibiotic courses, the intestine can be quickly restored with its own, ideally compatible microorganisms, avoiding relapses of IBS.

Conclusions

Irritable bowel syndrome is not a sentence or just a "nerve disease" that should be treated with painkillers or sedatives. It is a complex pathology of the "gut-brain" axis, which has a clear biological basis in the form of dysbiosis, inflammation and impaired intestinal barrier functions. The transition from standardized, blind medical protocols to personalized omics diagnostics, targeted use of clinically proven pharmabiotics and individual nutrition allows us to break this vicious circle and restore the patient's full health.

Short questions and answers on the topic (Q&A)

1. Why do regular pharmacy probiotics often not help with IBS, and sometimes even make the condition worse?

Answer: Most popular mass-market probiotics contain 20-30 different strains of bacteria in one pill, which are prescribed "blindly" without analyzing the patient's microbiome. Once in the intestines, these foreign bacteria begin to compete for resources and can aggressively suppress not only pathogens, but also the remnants of your own beneficial microflora. This creates additional imbalance, increases flatulence and does not eliminate the root cause of the disease.

2. How exactly are microbes in the gut related to pain and the nervous system in IBS?

Answer: The gut contains its own enteric nervous system (over 100 million neurons) and communicates continuously with the brain via the vagus nerve. Beneficial gut bacteria are involved in the production of neurotransmitters such as serotonin and GABA, which regulate mood and pain sensitivity. When the beneficial bacteria die (dysbiosis), this communication is disrupted: receptors become hypersensitive, which causes cramps, pain and anxiety.

3. What specific changes occur in the microbiome of a person with irritable bowel syndrome?

Answer: IBS causes a loss of overall biodiversity and a shift in pH to the alkaline side. The number of bacteria (e.g. Faecalibacterium prausnitzii ) that produce butyric acid (butyrate) — the main source of energy and protection for the intestinal walls — drops dramatically. Instead, the vacated space is quickly taken by pathogenic gram-negative bacteria that contain toxins (LPS), which leak into the bloodstream and provoke chronic inflammation.

4. What are “pharmabiotics” and how do they differ from regular probiotics in the treatment of IBS?

Answer: Pharmabiotics are new generation biologics with clinically proven, targeted action on specific disorders. Their main difference is personalization. After passing the tests, the pharmabiotic is selected so that its author's strains purposefully destroy the pathogens (inflammation agents) detected in the patient and categorically do not suppress his own, native microflora (commensals), allowing it to recover.